Role of positron emission tomography imaging in metabolically active renal cell carcinoma

V Karivedu, AL Jain, TJ Eluvathingal, A Sidana - Current urology reports, 2019 - Springer
V Karivedu, AL Jain, TJ Eluvathingal, A Sidana
Current urology reports, 2019•Springer
Abstract Purpose of Review The clinical role of fluorine-18 fluoro-2-deoxyglucose (FDG)-
positron emission tomography (PET) in renal cell carcinoma (RCC) is still evolving. Use of
FDG PET in RCC is currently not a standard investigation in the diagnosis and staging of
RCC due to its renal excretion. This review focuses on the clinical role and current status of
FDG PET and PET/CT in RCC. Recent Findings Studies investigating the role of FDG PET in
localized RCC were largely disappointing. Several studies have demonstrated that the use …
Purpose of Review
The clinical role of fluorine-18 fluoro-2-deoxyglucose (FDG)-positron emission tomography (PET) in renal cell carcinoma (RCC) is still evolving. Use of FDG PET in RCC is currently not a standard investigation in the diagnosis and staging of RCC due to its renal excretion. This review focuses on the clinical role and current status of FDG PET and PET/CT in RCC.
Recent Findings
Studies investigating the role of FDG PET in localized RCC were largely disappointing. Several studies have demonstrated that the use of hybrid imaging PET/CT is feasible in evaluating the extra-renal disease. A current review of the literature determines PET/CT to be a valuable tool both in treatment decision-making and monitoring and in predicting the survival in recurrent and metastatic RCC.
Summary
PET/CT might be a viable option in the evaluation of RCC, especially recurrent and metastatic disease. PET/CT has also shown to play a role in predicting survival and monitoring therapy response.
Springer
展开收起
被引用次数：25 相关文章 所有 5 个版本
以上显示的是最相近的搜索结果。 查看全部搜索结果